Pharmaceutical Product Development, Llc - Oct 6, 2021 Form 3/A - Amendment Insider Report for Science 37 Holdings, Inc. (SNCE)

Role
10%+ Owner
Signature
Jaguar Holding Company II By: /s/ Julia James, Name: Julia James, Title: General Counsel and Secretary
Stock symbol
SNCE
Transactions as of
Oct 6, 2021
Transactions value $
$0
Form type
3/A - Amendment
Date filed
11/8/2021, 03:09 PM
Date Of Original Report
Oct 18, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SNCE Common Stock 17.4M Oct 6, 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. are held of record by Pharmaceutical Product Development, LLC ("Pharma LLC"). Wildcat Acquisition Holdings (UK) Limited ("Wildcat") is the sole member of Pharma LLC; Jaguar Holding Company II ("Jaguar II") is the sole shareholder of Wildcat; Jaguar Holding Company I, LLC ("Jaguar I") is the sole shareholder of Jaguar II; Eagle Holding Company II, LLC ("Eagle II") is the sole member of Jaguar I; and PPD, Inc. is the sole member of Eagle II. By virtue of such relationships, each of the reporting persons may be deemed to have beneficial ownership over such shares of common stock.
F2 This report on Form 3/A is jointly filed by the reporting persons. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein.

Remarks:

This Form 3/A amends and restates the original Form 3 filed by the Reporting Persons on October 18, 2021 (the "Original Form 3"). This amendment is being filed to correct the number of securities reported as beneficially owned by the Reporting Persons in the Original Form 3.